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CLINICAL AND COST OUTCOMES OF VENOUS THROMBOEMBOLISM 
IN PATIENTS WHO UNDERWENT MAJOR ORTHOPEDIC SURGERY
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1STATinMED Research/University of Michigan, Ann Arbor, MI, USA; 2STATinMED Research, 
Ann Arbor, MI, USA
OBJECTIVES: To evaluate the effects of venous thromboembolism (VTE) occurring 
within 30 days of hospital discharge after major orthopedic surgery on inpatient costs 
and mortality within 1 year after initial hospitalization for the surgery. METHODS: 
U.S. national Medicare data was used for this analysis. All patients who underwent 
total hip replacement (THR) (n = 51,108) or total knee replacement (TKR) (n = 
115,627) surgery were identiﬁ ed. VTE events were diagnosed within the ﬁ rst 30 days 
and within 1 year post-discharge. Multivariate regression was used to control for 
differences in baseline characteristics in patients with and without VTE events. Total 
cost was measured as Medicare cost plus beneﬁ ciary out-of-pocket cost. RESULTS: 
VTE occurred in 0.74% of patients undergoing THR. For patients with VTE versus 
no VTE, mortality was higher (2.9% vs. 0.4%, P < 0.001). Medicare and total health 
care cost, including the beneﬁ ciary cost share in 1 year, were not different for VTE 
versus no VTE ($19,300 vs. $19,044, p = 0.817), but the beneﬁ ciary cost share was 
higher for VTE ($3,274 vs. $1,966, P < 0.001). VTE occurred in 0.70% of patients 
undergoing TKR. For patients with VTE versus no VTE, mortality was higher (2.5% 
vs. 0.15%, P < 0.001). Total health care cost, including the beneﬁ ciary cost share in 
1 year, was not different for VTE versus no VTE ($17,970 vs. $16,766, p = 0.142), 
but the Medicare and beneﬁ ciary cost shares were both slightly higher for VTE ($3,274 
vs. $1,966 and $2,650 vs. $1,630 for THR and TKR patients, respectively, P < 0.001). 
CONCLUSIONS: VTE after major orthopedic surgery is associated with higher mor-
tality compared with no VTE. VTE did not affect total health care costs in 1 year, 
but beneﬁ ciary costs were higher. Risk-adjusted total, Medicare, and beneﬁ ciary health 
care costs were signiﬁ cantly higher for major orthopedic surgery patients with VTE 
(P < 0.001).
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COMPARISON OF ADVERSE EVENTS OF MEDICARE PATIENTS WHO 
UNDERWENT KNEE REPLACEMENT SURGERY AND EXPERIENCED 
VENOUS THROMBOEMBOLISM VERSUS NO VENOUS 
THROMBOEMBOLISM
Wang L1, Dysinger A1, Baser O2
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OBJECTIVES: To estimate re-hospitalization and bleeding rates during the 30 days 
after a venous thromboembolism (VTE) event in patients who underwent knee replace-
ment surgery and to compare the outcomes with patients who did not suffer VTE. 
METHODS: Based on 2004–2006 national Medicare claims, all patients who under-
went knee replacement surgery were identiﬁ ed. The 30 days follow-up event rates for 
patients who had a VTE event during their initial hospitalization were calculated. 
Events were compared between patients who suffered a VTE event and those who did 
not. Risk adjustment was done using propensity score matching (using the ProbChoi-
ceTM algorithm) controlling for baseline demographic and clinical characteristics 
between patients with and without VTE. RESULTS: In patients who underwent total 
knee replacement surgery (n = 104,952), 1.9% had post-operative VTE events during 
their initial hospitalization. Almost 69% (n = 1377) of these patients had deep vein 
thrombosis (DVT), 25% (n = 501) had pulmonary embolism (PE), and 6% (n = 119) 
had both DVT and PE. The overall likelihood of mortality was four times higher for 
VTE patients versus those without VTE (1.35% vs. 0.35%). Patients with VTE during 
their initial hospitalization were more likely to be hospitalized in 30 days compared 
to patients without an event during the same hospital stay (16.62% vs. 8.00%). In 
30 days after the event, patients with VTE were more likely to have bleeding (9.31% 
vs. 2.18%). CONCLUSIONS: VTE events during initial hospitalization for total knee 
replacement surgery patients increased the adverse events compared with no VTE 
events.
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INTENSIVE MONITORING SYSTEM
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OBJECTIVES: Adverse drug reactions (ADR) appear more frequently then what is 
actually reported and registered. The aim was to establish intensive monitoring system 
and to analyze ADR in hospitalized patients. METHODS: Prospective study covered 
200 patients hospitalized in Cardiology Center, Clinical Center of Montenegro. ADR 
were collected in the following way: patients were interviewed on the basis of the 
symptoms list and any signs which could point to eventual ADR. Secondly, lab tests 
and other available parameters were observed. RESULTS: At the time when interviews 
took place, patients received on average 7.96 ± 2.63 medicines (2–17). In total, 67 
patients (34%) had 75 ADR. Twenty-one ADR (28%) are classiﬁ ed as serious. Fifty-
four ADR have resulted in the recovery of the patient (72%), eight had as an outcome 
prolonged hospitalization (11%), another 8 were life threatening (11%), while 5 ADR 
(6%) were the cause of the hospitalization. The most frequent ADR which had as an 
outcome admission to hospital were caused by digoxin (40%), prolonged hospital stay 
by furosemide (38%), while the most frequent registered ADR which were life threat-
ening were caused by streptokinase (50%). CONCLUSIONS: Monitoring ADR in 
patients using cardiovascular drugs is a matter of importance since this class of medi-
cine is usually used by elderly patients with critical conditions and underlying 
diseases.
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SPONTANEOUS REPORTING OF ADVERSE DRUG REACTIONS 
INVOLVING HOSPITALIZED CARDIAC PATIENTS
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OBJECTIVES: Adverse drug reactions (ADR) in hospital are a signiﬁ cant cause of 
morbidity and mortality. The aim is to analyze the ADR which have been collected 
through doctors’ and medical technicians’ spontaneous reporting. METHODS: The 
prospective study covered 655 patients hospitalized in Cardiology Center of Clinical 
Center of Montenegro. ADR were collected by spontaneous reporting. According to 
the criteria of World Health Organization, for every ADR causality assessment, sever-
ity, type, outcome, level of intervention and place of manifestation of ADR was 
established. RESULTS: In the 6 month period of research at the Cardiology Center, 
655 patients were hospitalized with the average age of 60.72 ± 11.36 years. With 
spontaneous reporting, 22 patients had 22 ADR which were noted. Doctors reported 
a statistically signiﬁ cant larger number of ADR (68%) than medical technicians 
(32%), P < 0,01. Nine patients (41%) had serious ADR with the following outcome: 
21 ADR were the cause of the hospitalization (22%), four ADR resulted in the 
extended hospitalization (44%), and 3 were life threatening (33%). The most frequent 
serious ADR were reported spontaneously by doctors and medical technicians and 
were caused by streptokinase (33%). The most frequent symptoms which the patients 
had as a consequence of ADR were: fainting (27%), headache (18%), weakness 
(14%), vertigo (14%) and vomiting (9%). CONCLUSIONS: Considering increased 
use of cardiovascular drugs and limitations in pre-marketing trials for drug safety 
evaluation, post marketing evaluation of adverse drug reactions induced by this class 
of medicinal products seems necessary.
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EVALUATION OF CLINICAL AND DIRECT ECONOMIC OUTCOMES 
FOLLOWING AN ACUTE CORONARY EVENT AMONG PATIENTS WITH 
SUBOPTIMAL HDL-C OR TRIGLYCERIDES ADMINISTERED EITHER 
STATIN AND NIACIN EXTENDED-RELEASE OR STATIN 
MONOTHERAPY
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OBJECTIVES: To compare the risk of subsequent coronary event (SCE) and associ-
ated costs between patients maintaining statin monotherapy (SM) or augmenting with 
niacin extended-release (NER) after an acute coronary event (ACE). METHODS: 
Patients with an ACE between January 1, 2004 and March 31, 2009 were identiﬁ ed 
(Index Date was deﬁ ned as the earliest ACE). Patients age ≥18, ≥6 months eligibility 
pre- and post-Index Date, ≥1 statin ﬁ ll and no statin augmenting ﬁ ll 6 months before 
the Index Date, and sub-optimal baseline HDL-C (<40 or <50 mg/dL for men and 
women) or triglyceride (>150 or >200 mg/dL for diabetic and non-diabetic) were 
included. Cohorts were determined based on NER or SM ﬁ lls within 6 months of the 
Index Date (Cohort ID Period). Patients with alternative lipid agents or SCE during 
the Cohort ID Period were excluded. Outcomes included SCE and event-related 
medical costs. SCE risk was compared using Cox proportional hazards models, while 
costs were compared via generalized linear models. Multivariate analyses controlled 
for age, gender, health coverage, geography, co-morbidities, concomitant medications, 
baseline lipids, and severity of initial ACE. RESULTS: A total of 1998 patients added 
NER (n = 145) or maintained SM (n = 1,853) and met all study criteria. NER patients 
were younger (57 ± 8 vs. 61 ± 11, P < 0.0001), less likely female (8% vs. 33%, P = 
0.002), and had lower baseline LDL-C (81 ± 32 vs. 99 ± 41; P < 0.0001), HDL-C (34 
± 7 vs. 40 ± 9; P < 0.0001), and triglycerides (185 ± 118 vs. 208 ± 131; P = 0.0290). 
Compared to SM, NER patients had a 43% lower SCE risk (hazard ratio: 0.57, 
95%CI: 0.35–0.94; P = 0.0274). Clinical ﬁ ndings corresponded with 56% reduction 
in adjusted annual event-related costs compared to SM (0.44; 95% CI: 0.25–0.80 p 
= 0.0068). CONCLUSIONS: Among patients requiring comprehensive lipid manage-
ment, NER demonstrated lower SCE risk compared to SM, consequently reducing 
annual event-related medical costs following an ACE.
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RATE OF SUBSEQUENT CORONARY EVENTS AND DIRECT ECONOMIC 
OUTCOMES FOLLOWING AN ACUTE CORONARY EVENT BETWEEN 
PATIENTS AUGMENTING STATIN TO FURTHER REDUCE LDL-C VS. 
IMPROVING A COMPREHENSIVE LIPID PROFILE
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OBJECTIVES: Compare the annual subsequent coronary event rate (ASCER) and 
associated costs between patients initiating adjunct therapy with either niacin 
extended-release (NER) for comprehensive lipid panel management or ezetimibe (EZE) 
for continued LDL-C reduction after an acute coronary event (ACE). METHODS: 
Patients with an ACE between January 1, 2004 and May 31, 2009 were identiﬁ ed 
